Psoriasis Market Report 2025

This Psoriasis market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The psoriasis market size has grown rapidly in recent years. It will grow from $26.56 billion in 2024 to $29.5 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to epidemiology, patient awareness and education, healthcare infrastructure and access.

The psoriasis market size is expected to see strong growth in the next few years. It will grow to $42.34 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to regulatory approvals, patient preferences, aging population, increased awareness, introduction of novel therapies. Major trends in the forecast period include advancements in research and development, biologics and targeted therapies, oral small molecule therapies, personalized medicine, telemedicine and digital health, patient-centric care, biosimilars, artificial intelligence and machine learning.

The increasing prevalence of psoriasis patients is a driving force behind the growth of the psoriasis market. Psoriasis, a skin condition, is influenced by factors such as the immune system, genetics, and environmental factors. Over recent years, the surge in psoriasis cases can be primarily attributed to climate changes, elevated stress levels, and unhealthy lifestyles. The World Psoriasis Day consortium reports that a significant 2 to 3% of the global population, which translates to 125 million individuals, suffers from psoriasis. Consequently, the escalating number of psoriasis patients is expected to be a key driver for the growth of the psoriasis market in the foreseeable future.

The growing geriatric population is anticipated to drive the expansion of the psoriasis market in the coming years. The geriatric population comprises individuals aged 65 and older. This demographic has a significantly higher prevalence of conditions such as hypertension, diabetes mellitus, and elevated blood glucose levels, which can exacerbate psoriasis symptoms. For example, in January 2022, the Congressional Budget Office, a US-based federal agency, reported that the population eligible for Social Security payroll taxes and benefits is projected to increase from 342 million in 2024 to 383 million by 2054. This rise is primarily attributed to the substantial growth of the 65-and-older age group, contributing to an aging population. As a result, the increasing geriatric population is driving the growth of the social assistance market.

An emerging trend in the psoriasis market is the use of combination therapy. Combination therapy involves the simultaneous use of two different psoriasis treatments. Combining drugs with distinct mechanisms of action (combination therapy) often results in more significant treatment effects compared to monotherapy (using a single drug). Studies indicate that combination therapy provides more effective relief from psoriasis symptoms and is associated with fewer side effects. An example of combination therapy for treating active Psoriatic Arthritis (PsA) is the combination of Taltz (ixekizumab) with methotrexate, a development by Eli Lilly and Company.

Major companies operating in the psoriasis market are intensifying their efforts to introduce innovative products and secure approval from regulatory agencies, aiming to maximize their market revenues. The drug development and approval process is intricate and time-consuming, requiring drug sponsors to navigate the regulatory framework and marketing pathways to ensure safety and effectiveness. As an illustration, in September 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO, marking the first approved treatment for generalized pustular psoriasis (GPP) flare-ups in adults. SPEVIGO is a novel, highly selective antibody designed to inhibit the interleukin-36 receptor (IL-36R) activation, a pivotal component of an immune system signaling pathway linked to GPP development. GPP, characterized by periods of widespread eruptions of sterile pustules, is a rare and potentially life-threatening neutrophilic skin condition.

The process of approving psoriasis drugs has become more streamlined on a global scale, as evidenced by the increasing approvals of drugs for psoriasis in recent years. Some notable examples include the regulatory approval of SKYRIZI (risankizumab) for plaque psoriasis treatment in Japan and the Center for Drug Evaluation and Research's approval of Avsola (infliximab-axxq) for treating plaque psoriasis. This simplified drug approval process is expected to drive the psoriasis drugs market in the forecast period.

Psoriasis is a skin condition characterized by the development of a rash with itchy, scaly patches, typically affecting areas such as the knees, elbows, trunk, and scalp. The underlying cause is often related to an immune system dysfunction where infection-fighting cells mistakenly attack healthy skin cells.

The primary categories of drugs used to manage psoriasis include interleukin inhibitors, corticosteroids, anti-inflammatories, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates and can also be synthesized as medications. These drugs come in various forms, including small molecules and biologics, and are applied to treat different manifestations of the disease, such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. They are administered via various routes, including oral, topical, and injectable methods and can be obtained through hospitals, retail pharmacies, and e-commerce channels.

The psoriasis market research report is one of a series of new reports that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the psoriasis market include AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc., AstraZeneca Inc., Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Forward Pharma AS, Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Dermira Inc., Galderma SA, GlaxoSmithKline PLC, Incyte Pharmaceuticals Corp., LEO Pharmacy.

North America was the largest region in the psoriasis market in 2024. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.